Rivus Pharmaceuticals, Inc.
Charlottesville, US · Founded 2019 · Delaware corporation · 3 known investors
Rivus develops oral medicines for cardiometabolic health using its proprietary development platform. Its lead candidate HU6 is an oral therapy in the Phase 2 AMPLIFY trial for MASH (chronic liver disease), and its pipeline includes RV-8451, an oral GLP-1 in IND-enabling studies for obesity.
BiotechDigital Health
Founders & leadership
AC
Allen CunninghamExecutive
NH
Nancy HargreavesExecutive
JD
Jayson DallasExecutive
SK
Shaharyar KhanExecutive
Board
FD
DD
PE
Patrick EnrightBoard director
IS
Ian SmithBoard director
RW
Rick WinninghamBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$223.5M disclosed across 4 rounds · 2019–2025
▶$57MraisedJan 2025 · 7 investors · PharmaceuticalsRule 506(b)
▶$57MraisedJan 2025 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert SchottExecutive Officer
- Shaharyar KhanExecutive Officer, Director
- Rick WinninghamDirector
- Allen CunninghamExecutive Officer, Director
- Jayson DallasExecutive Officer, Director
- Tom O'NeilExecutive Officer
- Derek DiRoccoDirector
- Ian SmithDirector
- Erin LavelleDirector
- Francesco De RubertisDirector
- Offering amount
- $57M
- Amount sold
- $57M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$66MraisedSep 2024 · 7 investors · PharmaceuticalsRule 506(b)
▶$66MraisedSep 2024 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ian SmithDirector
- Allen CunninghamExecutive Officer, Director
- Francesco De RubertisDirector
- Derek DiRoccoDirector
- Rick WinninghamDirector
- Shaharyar KhanExecutive Officer, Director
- Jayson DallasExecutive Officer, Director
- Nancy HargreavesExecutive Officer
- Offering amount
- $66M
- Amount sold
- $66M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$66MraisedSep 2024 · 7 investors · PharmaceuticalsRule 506(b)
▶$66MraisedSep 2024 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ian SmithDirector
- Allen CunninghamExecutive Officer, Director
- Francesco De RubertisDirector
- Rick WinninghamDirector
- Nancy HargreavesExecutive Officer
- Jayson DallasExecutive Officer, Director
- Derek DiRoccoDirector
- Shaharyar KhanExecutive Officer, Director
- Offering amount
- $66M
- Amount sold
- $66M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$34.5MraisedOct 2021 · 4 investors · PharmaceuticalsRule 506(b)
▶$34.5MraisedOct 2021 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shaharyar KhanExecutive Officer, Director
- Patrick EnrightDirector
- Jayson DallasDirector
- Allen CunninghamExecutive Officer, Director
- Francesco De RubertisDirector
- Offering amount
- $35M
- Amount sold
- $34.5M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapVivus18 shared keywordsVIVUS is a global pharmaceutical company that develops and commercializes therapies for patients with serious medical conditions and life-limiting diseases. It aims to provide healthcare providers with new treatment options to improve patient quality of life.
Corvuspharma16 shared keywordsCorvus is a clinical-stage biopharmaceutical company developing therapies for immune diseases and cancer. Its lead program, soquelitinib, is an oral therapy that selectively inhibits ITK to modulate immune system signaling pathways.
Robinhood13 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Rivus Pharmaceuticals, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Rivus Pharmaceuticals, Inc. do?
- Rivus develops oral medicines for cardiometabolic health using its proprietary development platform. Its lead candidate HU6 is an oral therapy in the Phase 2 AMPLIFY trial for MASH (chronic liver disease), and its pipeline includes RV-8451, an oral GLP-1 in IND-enabling studies for obesity.
- Who are Rivus Pharmaceuticals, Inc.'s investors?
- Rivus Pharmaceuticals, Inc.'s investors include Longitude Capital, Medicxi, RA Capital.
- How much funding has Rivus Pharmaceuticals, Inc. raised?
- Rivus Pharmaceuticals, Inc. has disclosed $223.5M raised across 4 rounds.
- Where is Rivus Pharmaceuticals, Inc. headquartered?
- Rivus Pharmaceuticals, Inc. is headquartered in Charlottesville, US.